Cel Sci CorpCVM

CEL-SCI Corporation is the public face of a long-running biotech experiment whose lead asset, Multikine, has been “investigational” since the Berlin Wall came down. The company’s own pipeline page lists the same programmes it has touted for years, with no revenue line in sight and no regulatory approvals on record. The technology page is equally candid: Multikine is a trademark that remains subject to FDA review in connection with future anticipated submissions, and LEAPS is described as an investigational platform technology. In short, the company’s product story is a loop of hopeful language rather than a loop of cash.

The operating reality is captured in the 10-Q for the quarter ended 31 March 2026. Net loss attributable to the parent was $5.5 million, operating loss $5.3 million, and operating cash flow drained $8.0 million. Research and development spend was $3.8 million, while capital expenditure was a polite zero. Total assets stood at $17.7 million against liabilities of $10.8 million, leaving shareholders’ equity at $6.9 million. Diluted loss per share was 67 cents on 8.1 million diluted shares. These are not rounding errors; they are the actual numbers filed with the SEC.

The company’s latest DEF 14A, filed 2 July 2026, reminds readers that consultants must deliver bona fide services and cannot be compensated for promoting CEL-SCI stock. The document also clarifies that vesting periods apply to employees and non-employee advisors alike. For the year ended 30 September 2025, the company states it issued no common shares to officers or directors in return for services, a disclosure that reads like a footnote to a larger question: how will CEL-SCI fund its programmes when its balance sheet is already underwater? The SEC filings do not yet contain a revenue line, a regulatory approval, or a clear pathway to monetisation.

For readers who like their biotech with a side of governance, the 8-K filed 16 June 2026 shows routine director elections and reappointment of auditors, but no material news that changes the company’s cash arithmetic. The SEC submissions index confirms the same set of quarterly and annual reports that underpin the 10-Q and DEF 14A. The company’s investor materials stress that Multikine is the registered trademark of an investigational therapy subject to future FDA review; the filings stress that the company has yet to generate sales or approvals. The gap is the story.

There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The share count and loss per share are, however, plainly visible in the 10-Q. The pipeline and technology pages are public, but they do not contain live clinical data, revenue metrics, or regulatory milestones. Until that changes, the market file is a ledger of red ink rather than a tale of therapeutic breakthrough.

What is proven: the company is a pre-revenue biotech with heavy R&D spend and shrinking cash. What is not proven: any product that has reached paying patients or regulators. What would deepen the file next: a Phase III read-out with a survival endpoint, a regulatory filing acceptance letter, or a partnering transaction that monetises the pipeline before the cash runway expires.